203,726 Shares in REGENXBIO Inc. $RGNX Bought by Walleye Capital LLC

Walleye Capital LLC acquired a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 203,726 shares of the biotechnology company’s stock, valued at approximately $2,441,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. AQR Capital Management LLC grew its position in shares of REGENXBIO by 2,247.7% in the first quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company’s stock valued at $4,437,000 after purchasing an additional 594,161 shares during the period. Jane Street Group LLC increased its stake in shares of REGENXBIO by 151.1% during the first quarter. Jane Street Group LLC now owns 414,067 shares of the biotechnology company’s stock worth $2,961,000 after purchasing an additional 249,156 shares in the last quarter. Franklin Resources Inc. acquired a new position in shares of REGENXBIO during the 2nd quarter worth about $239,000. American Century Companies Inc. lifted its stake in REGENXBIO by 8.4% in the 2nd quarter. American Century Companies Inc. now owns 110,066 shares of the biotechnology company’s stock valued at $904,000 after buying an additional 8,487 shares in the last quarter. Finally, Prudential Financial Inc. purchased a new position in REGENXBIO in the 2nd quarter valued at about $87,000. 88.08% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Steve Pakola sold 2,161 shares of REGENXBIO stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $13.64, for a total transaction of $29,476.04. Following the transaction, the insider owned 213,009 shares in the company, valued at $2,905,442.76. The trade was a 1.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders sold 58,494 shares of company stock valued at $718,232. 14.22% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

RGNX has been the topic of several research analyst reports. Wall Street Zen upgraded REGENXBIO from a “strong sell” rating to a “hold” rating in a report on Saturday, August 8th. Bank of America reduced their target price on REGENXBIO from $25.00 to $14.00 and set a “buy” rating for the company in a report on Friday, May 15th. Barclays downgraded REGENXBIO from an “overweight” rating to a “hold” rating in a research report on Friday, August 7th. Zacks Research raised REGENXBIO from a “strong sell” rating to a “hold” rating in a research note on Wednesday. Finally, HC Wainwright dropped their price target on REGENXBIO from $26.00 to $23.00 and set a “buy” rating for the company in a research report on Monday. Nine research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $23.73.

REGENXBIO Trading Up 1.0%

RGNX stock opened at $10.77 on Friday. The company has a market cap of $710.93 million, a price-to-earnings ratio of -2.84 and a beta of 0.94. REGENXBIO Inc. has a 12 month low of $5.45 and a 12 month high of $16.19. The firm has a 50-day moving average of $10.42 and a two-hundred day moving average of $9.29.

REGENXBIO (NASDAQ:RGNX) last released its earnings results on Thursday, August 6th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.35. The business had revenue of $108.02 million for the quarter, compared to analyst estimates of $97.63 million. REGENXBIO had a negative net margin of 112.58% and a negative return on equity of 220.07%. As a group, equities analysts forecast that REGENXBIO Inc. will post -3.91 earnings per share for the current year.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.